Biotech Values

[go seek]

IDIX: I agree. JP did not have to say it... yet he did.
IDIX would not have made such a bold move w/o a nod from NVS.

Plus the partner(s) IDIX is negotiating with wants to see this combination trial, as much as IDIX does.

You and I have been listened to enough IDIX CC's to know "the story" ...by reading between the lines.

It is a very exciting time for IDIX and IDIX shareholders.


We continue to have discussions with potential corporate partners on the IDX184 program and remain optimistic about our prospect for securing partnership for this program this year.

We are also very excited about the pre-clinical and clinical data observed with IDX320, our HCV protease inhibitor. Based on the in vitro potency seen in the replicon model combined with multi-genotypic coverage and the potential for once-daily dosing suggested by its PK profile in the phase I study that was presented at EASL. We hope that IDX320 may offer substantial improvements over all the protease inhibitors.

Based on the emerging profiles of IDX184 and IDX320, we intend to accelerate our timeline for evaluating these two direct acting antiviral drug candidates. Subject to discussions with regulatory authorities, our plan is to conduct, first, a drug-drug interaction study of IDX184 and IDX320 in healthy volunteers and then to initiate a combination study in HCV-infected patients in the second half of this year. JP Sommadossi, CEO